ArticleInfectious diseases and therapy2025
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTransient viremia can occur in people with human immunodeficiency virus (HIV), often referred to as people with HIV (PWH), and is sometimes related to poor adherence to antiretroviral therapy (ART). Guidelines recommend achieving virologic resuppression with existing ART regimens while addressing the reasons for the lack of virologic control. However, there are limited clinical trial data on the effectiveness of the strategy of continuing the same ART regimen in treatment-experienced PWH following a period of viremia. This was a post hoc pooled analysis of eight clinical studies in PWH receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).
methodsViremic events occurring in participants receiving B/F/TAF were defined as ≥ 1 viral load (VL) measurement of ≥ 50 copies/mL after virologic suppression (VL < 50 copies/mL). Outcomes after viremic events were categorized as: virologic resuppression (≥ 1 subsequent VL < 50 copies/mL); continued viremia (all subsequent VLs ≥ 50 copies/mL); or not evaluable (no subsequent VL assessment). Adherence was calculated by pill count from returned pill bottles.
resultsThe analysis included 2801 participants. A total of 411 viremic events were experienced by 290 participants, 50% of whom were treatment naïve at B/F/TAF initiation, and the other 50% were virologically suppressed. A total of 91 participants experienced ≥ 1 viremic event of ≥ 1000 copies/mL. The proportion of viremic events followed by resuppression on B/F/TAF was 90.3%, rising to 96.6% when nonevaluable data were excluded. The median (quartile [Q]1, Q3) time from a viremic event to documented resuppression was 22 (18, 36) days. Among 13 participants with continued viremia, 11 (84.6%) prematurely discontinued B/F/TAF. No treatment-emergent resistance was observed in participants with continued viremia. A significantly higher proportion of participants with a viremic event had < 85% adherence compared with those without (10.0% and 4.2%, respectively; p = 0.0003).
conclusionsMost participants receiving B/F/TAF experienced no viremic events. The vast majority of viremic events resolved with B/F/TAF continuation, without the need for treatment change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.